Stacey E. Rudd - Concepedia

Author

Stacey E. Rudd

The University of Melbourne ORCID

Also Known As

Rudd, Stacey E., S. Rudd, Stacey E Rudd, Stacey E. Rudd, Stacey Rudd

Publications

529

Citations

H-Index

Concepts

All Affiliations

The University of Melbourne Peter MacCallum Cancer Centre Austin Health Olivia Newton-John Cancer Wellness & Research Centre La Trobe University

About

Stacey E. Rudd is an author at The University of Melbourne specializing in molecular imaging, engineering, and bioimaging.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	2	2	100
2	Health Sciences	1	1	64
3	Natural Sciences	1	1	36
4	Biochemistry	1	1	36
5	Biomolecular Engineering	1	1	36

Stacey E. Rudd

Publications

400

Citations

H-Index

Page 1

	Year	Citations
A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies Stacey E. Rudd, Peter Roselt, Carleen Cullinane, Chemical Communications	2016	104
Copper, gallium and zirconium positron emission tomography imaging agents: The importance of metal ion speciation Lachlan E. McInnes, Stacey E. Rudd, Paul S. Donnelly Coordination Chemistry Reviews Positron Emission TomographyEngineeringMedical ImagingMicroscopyMetal Ion Speciation	2017	64
A Versatile Approach for the Site‐Specific Modification of Recombinant Antibodies Using a Combination of Enzyme‐Mediated Bioconjugation and Click Chemistry Karen Alt, Brett M. Paterson, Erik Westein, Angewandte Chemie International Edition	2015	51
A Versatile Approach for the Site‐Specific Modification of Recombinant Antibodies Using a Combination of Enzyme‐Mediated Bioconjugation and Click Chemistry Karen Alt, Brett M. Paterson, Erik Westein, Angewandte Chemie EngineeringMolecular BiologyPlatelet AggregatesClick ChemistryAnalytical Ultracentrifugation	2015	36
Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer Asif Noor, Jessica Van Zuylekom, Stacey E. Rudd, Journal of Medicinal Chemistry	2020	22
<i>In Vitro</i> and <i>In Vivo</i> Evaluation of <sup>89</sup>Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy Ingrid J.G. Burvenich, Fook-Thean Lee, Nancy Guo, Theranostics	2016	20
Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor Stacey E. Rudd, Jessica Van Zuylekom, Anna Raicevic, Chemical Science	2021	20
Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo Christian Wichmann, Stan Poniger, Nancy Guo, Nuclear Medicine and Biology	2023	18
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with <sup>89</sup> Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol Fiona Hegi‐Johnson, Stacey E. Rudd, Christian Wichmann, BMJ Open	2022	17
PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study Fiona Hegi‐Johnson, Stacey E. Rudd, Christian Wichmann, International Journal of Radiation OncologyBiologyPhysics	2023	15

Page 1